A new study shows that the cancer protein MCL1 connects two key hallmarks of cancer: resistance to cell death and altered ...

Interrupting one function of a protein that plays a key role in cell signaling could enable the development of new cancer treatments, according to a study led by Dr. Martin Taylor at the Warren Alpert ...

A large, multi-institution study led by a Brown University physician-scientist could have important implications for the development of new classes of cancer therapeutics.

A study by the Mildred Scheel Early Career Center group led by Dr. Mohamed Elgendy at the TUD Faculty of Medicine provides fundamental insights into cancer biology. Published in Nature Communications, ...

The researchers have succeeded in tracing two classic hallmarks of cancer – the evasion of apoptosis (a form of programmed cell death) and the dysregulation of energy metabolism – back to a common ...

A study published in iMetaMed reveals that the mTOR inhibitor Everolimus treats ulcerative colitis through a two-pronged approach: inhibiting the CLEC4E inflammatory pathway in macrophages and ...

AI therapeutics company built on causal biology, today announced the publication of research in Nature Communications validating its POSH (Pooled Optical Screening in Human cells) platform. The study ...

The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET). This dual-therapy targets a pathway ...